403 related articles for article (PubMed ID: 33027952)
21. Topoisomerase Inhibitors and Targeted Delivery in Cancer Therapy.
You F; Gao C
Curr Top Med Chem; 2019; 19(9):713-729. PubMed ID: 30931860
[TBL] [Abstract][Full Text] [Related]
22. Anticancer potency of copper(II) complexes of thiosemicarbazones.
Singh NK; Kumbhar AA; Pokharel YR; Yadav PN
J Inorg Biochem; 2020 Sep; 210():111134. PubMed ID: 32673842
[TBL] [Abstract][Full Text] [Related]
23. DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic.
Holden JA
Curr Med Chem Anticancer Agents; 2001 May; 1(1):1-25. PubMed ID: 12678768
[TBL] [Abstract][Full Text] [Related]
24. Role of Protein Linked DNA Breaks in Cancer.
Allam WR; Ashour ME; Waly AA; El-Khamisy S
Adv Exp Med Biol; 2017; 1007():41-58. PubMed ID: 28840551
[TBL] [Abstract][Full Text] [Related]
25. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.
Etiévant C; Kruczynski A; Barret JM; Perrin D; van Hille B; Guminski Y; Hill BT
Cancer Chemother Pharmacol; 2000; 46(2):101-13. PubMed ID: 10972479
[TBL] [Abstract][Full Text] [Related]
26. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells.
López-Lázaro M; Willmore E; Austin CA
Mutat Res; 2010 Feb; 696(1):41-7. PubMed ID: 20025993
[TBL] [Abstract][Full Text] [Related]
27. The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation.
Zhao W; Jiang G; Bi C; Li Y; Liu J; Ye C; He H; Li L; Song D; Shao R
Oncotarget; 2015 Nov; 6(35):37871-94. PubMed ID: 26462155
[TBL] [Abstract][Full Text] [Related]
28. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
[TBL] [Abstract][Full Text] [Related]
29. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
[TBL] [Abstract][Full Text] [Related]
31. Salvicine, a novel DNA topoisomerase II inhibitor, exerting its effects by trapping enzyme-DNA cleavage complexes.
Meng LH; Zhang JS; Ding J
Biochem Pharmacol; 2001 Sep; 62(6):733-41. PubMed ID: 11551518
[TBL] [Abstract][Full Text] [Related]
32. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.
Perrin D; van Hille B; Barret JM; Kruczynski A; Etiévant C; Imbert T; Hill BT
Biochem Pharmacol; 2000 Apr; 59(7):807-19. PubMed ID: 10718339
[TBL] [Abstract][Full Text] [Related]
33. Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors.
de Camargo MS; De Grandis RA; da Silva MM; da Silva PB; Santoni MM; Eismann CE; Menegário AA; Cominetti MR; Zanelli CF; Pavan FR; Batista AA
Biometals; 2019 Feb; 32(1):89-100. PubMed ID: 30506342
[TBL] [Abstract][Full Text] [Related]
34. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
Sehested M; Jensen PB
Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
[TBL] [Abstract][Full Text] [Related]
35. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
Fortune JM; Osheroff N
Prog Nucleic Acid Res Mol Biol; 2000; 64():221-53. PubMed ID: 10697411
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of novel coumarin nucleus-based DPA drug-like molecular entity: In vitro DNA/Cu(II) binding, DNA cleavage and pro-oxidant mechanism for anticancer action.
Khan S; Malla AM; Zafar A; Naseem I
PLoS One; 2017; 12(8):e0181783. PubMed ID: 28763458
[TBL] [Abstract][Full Text] [Related]
37. DNA topoisomerases as molecular targets for anticancer drugs.
Buzun K; Bielawska A; Bielawski K; Gornowicz A
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1781-1799. PubMed ID: 32975138
[TBL] [Abstract][Full Text] [Related]
38. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
39. International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents.
Anderson RD; Berger NA
Mutat Res; 1994 Aug; 309(1):109-42. PubMed ID: 7519727
[TBL] [Abstract][Full Text] [Related]
40. DNA topoisomerase I and II as targets for rational design of new anticancer drugs.
Cummings J; Smyth JF
Ann Oncol; 1993 Aug; 4(7):533-43. PubMed ID: 8395870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]